Use Of Chimeric Antigen Receptor-modified T Cells To Treat Cancer


The full document isn't yet available to us from the patent office.


The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.


Information currently unavailable.

Download PDF
Document Preview
Document History
  • Publication: Apr 11, 2018
  • Application: Dec 9, 2011
    EP EP 17191702 A
  • Priority: Dec 9, 2011
    EP EP 17153799 A
  • Priority: Dec 9, 2011
    EP EP 11846757 A
  • Priority: Jun 29, 2011
    US US 201161502649 P
  • Priority: Dec 9, 2010
    US US 42147010 P

Download Citation

Sign in to the Lens